Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (7619)	5/6/1999 10:36:00 AM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

MK: Thanks for the link. Message 9353391 It will be interesting to actually read the methodology and results of this study. Several questions that are obviously not addressed in the PR release are: - Why were the results combined for both "Viagra failures" and "patients experiencing side effects with Viagra"? What was the efficacy rate within these two groups? The % of success in the Viagra failure group would be a particularly interesting % to know. -Did the patient group that experienced side effects with Viagra include patients in which Viagra may have been effective but is contraindicated ie Nitrates? What was the success rate in this group? -Was this a placebo controlled study or open label? What would have been the placebo effect in these groups? -How were the patients selected? -What was the side effect profile of the drugs used? -Why did 35% of the patients chose to discontinue using the drugs used in the study? Were these patients responders or non-responders? BigKNY3